Evaluation of Early Tocilizumab Effect on Multiorgan Dysfunction in Critically Ill Patients With COVID-19: A Propensity Score-Matched Study. (June 2023)

• Record Type: Journal Article
• Authors: Aljuhani, Ohoud; Korayem, Ghazwa B.; Altebainawi, Ali F.; Al Harthi, Abdullah; Badreldin, Hisham A.; Alsalloum, Muath A.; Eljaaly, Khalid; Alharbi, Aisha; Aljehani, Rowina; Vishwakarma, Ramesh; Alenazi, Abeer A.; Alalawi, Mai; Alissa, Abdulrahman; Al Aamer, Kholoud; Al Enazi, Huda; Almusallam, Mohammed; Alshehri, Abdulaziz; Bukhari, Rawan; Alasmari, Ghaday; AlQahtani, Maha M.; Al Shammari, Sultanah; Alsulaymi, Hatim O.; Al Sulaiman, Khalid
• Is Part Of: Journal of intensive care medicine. Volume 38:Number 6(2023)
• Page Start: 534
• Page End: 543
• Publication Date: 2023-06
• Subjects: COVID-19 -- SARS-CoV-2 -- tocilizumab -- IL-6 inhibitors -- multiorgan dysfunction -- acute kidney injury -- liver injury -- mortality -- critically ill -- intensive care units (ICUs); Critical care medicine -- Periodicals; Critical Care -- Periodicals; Soins intensifs -- Périodiques; Soins intensifs; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.02805
• DOI: 10.1177/08850666221150886
• Languages: English
• ISSNs: 0885-0666

Abstract

Background: Tocilizumab (TCZ) has been proposed as potential rescue therapy for severe COVID-19. No previous study has primarily assessed the role of TCZ in preventing severe COVID-19-related multiorgan dysfunction. Hence, this multicenter cohort study aimed to evaluate the effectiveness of TCZ early use versus standard of care in preventing severe COVID-19-related multiorgan dysfunction in COVID-19 critically ill patients during intensive care unit (ICU) stay.Methods: A multicenter, retrospective cohort study includes critically ill adult patients with COVID-19 admitted to the ICUs. Patients were categorized into two groups, the treatment group includes patients who received early TCZ therapy within 24 hours of ICU admission and the control group includes patients who received standard of care. The primary outcome was the multiorgan dysfunction on day three of the ICU admission. The secondary outcomes were 30-day, and in-hospital mortality, ventilator-free days, hospital length of stay (LOS), ICU LOS, and ICU-related complications.Results: After propensity score matching, 300 patients were included in the analysis based on predefined criteria with a ratio of 1:2. Patients who received TCZ had lower multiorgan dysfunction score on day three of ICU admission compared to the control group (beta coefficient: −0.13, 95% CI: −0.26, −0.01, P -value = 0.04). Moreover, respiratory failure requiring MV was statistically significantly lower in patients who received early TCZ compared to the control group (OR 0.52; 95% CI 0.31, 0.91, P -value = 0.02). The 30-day and in-hospital mortality were significantly lower in patients who received TCZ than those who did not (HR 0.56; 95% CI 0.37, 0.85, P -value = 0 .006 and HR 0.54; 95% CI 0.36, 0.82, P -value = 0.003, respectively).Conclusion: In addition to the mortality benefits associated with early TCZ use within 24 hours of ICU admission, the use of TCZ was associated with a significantly lower multiorgan dysfunction score on day three of ICU admission in critically ill patients with COVID-19.